), the former Animal Health business of
), announced recently that it intends to expand its manufacturing
facility in Lincoln, Neb. Zoetis aims to facilitate the
production of high-quality, reliable drugs for veterinarians,
livestock offerings and the animals under their care through this
Through this move, the company intends to fulfill its
objective of being a world-class manufacturer of animal health
products by ensuring constant supply of high- quality therapies
Zoetis stated that the early construction work has commenced
and full fledged work for expanding the existing facility is
expected to start shortly. The entire process involves a
three-story expansion (19,000 square-feet) of the existing
production facility. This will facilitate the transfer of
products to Lincoln from a third-party manufacturer. The work is
expected to be completed in 2014.
We remind investors that Zoetis started trading on the New
York Stock Exchange from Feb 1, 2013. Last month, Pfizer gave up
its entire stake in Zoetis. Pfizer had announced its plans to
spin off its Animal Health business in Jun 2012.
Zoetis emphasizes on the discovery, development, manufacture
and marketing of veterinary vaccines and medicines. The company
focuses on farm as well as companion animals and has presence in
more than 120 countries. The Animal Health segment of Pfizer had
delivered sales of $4.3 billion in 2012, up 3% year over
Zoetis carries a Zacks Rank #3 (Hold). Companies such as
Biogen Idec Inc.
Jazz Pharmaceuticals Public Limited Company
) appear to be more attractive. Both stocks carry a Zacks Rank #1
BIOGEN IDEC INC (BIIB): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.